341 related articles for article (PubMed ID: 19657325)
1. The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy.
Clark PE
Kidney Int; 2009 Nov; 76(9):939-45. PubMed ID: 19657325
[TBL] [Abstract][Full Text] [Related]
2. VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.
Razafinjatovo CF; Stiehl D; Deininger E; Rechsteiner M; Moch H; Schraml P
Oncotarget; 2017 Feb; 8(6):10199-10212. PubMed ID: 28052007
[TBL] [Abstract][Full Text] [Related]
3. Significance of PI3K signalling pathway in clear cell renal cell carcinoma in relation to VHL and HIF status.
Tumkur Sitaram R; Landström M; Roos G; Ljungberg B
J Clin Pathol; 2021 Apr; 74(4):216-222. PubMed ID: 32467322
[TBL] [Abstract][Full Text] [Related]
4. Targeting HIF2α translation with Tempol in VHL-deficient clear cell renal cell carcinoma.
Sourbier C; Srivastava G; Ghosh MC; Ghosh S; Yang Y; Gupta G; Degraff W; Krishna MC; Mitchell JB; Rouault TA; Linehan WM
Oncotarget; 2012 Nov; 3(11):1472-82. PubMed ID: 23178531
[TBL] [Abstract][Full Text] [Related]
5. Role of VHL gene mutation in human renal cell carcinoma.
Arjumand W; Sultana S
Tumour Biol; 2012 Feb; 33(1):9-16. PubMed ID: 22125026
[TBL] [Abstract][Full Text] [Related]
6. Molecular biology of renal cell carcinoma.
Mellado B; Gascón P
Clin Transl Oncol; 2006 Oct; 8(10):706-10. PubMed ID: 17074668
[TBL] [Abstract][Full Text] [Related]
7. Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies.
Golshayan AR; Brick AJ; Choueiri TK
Future Oncol; 2008 Feb; 4(1):85-92. PubMed ID: 18241003
[TBL] [Abstract][Full Text] [Related]
8. Pseudohypoxia induced by miR-126 deactivation promotes migration and therapeutic resistance in renal cell carcinoma.
Liu W; Chen H; Wong N; Haynes W; Baker CM; Wang X
Cancer Lett; 2017 May; 394():65-75. PubMed ID: 28257806
[TBL] [Abstract][Full Text] [Related]
9. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway.
Blancher C; Moore JW; Robertson N; Harris AL
Cancer Res; 2001 Oct; 61(19):7349-55. PubMed ID: 11585776
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment.
Wierzbicki PM; Klacz J; Kotulak-Chrzaszcz A; Wronska A; Stanislawowski M; Rybarczyk A; Ludziejewska A; Kmiec Z; Matuszewski M
Int J Oncol; 2019 Aug; 55(2):371-390. PubMed ID: 31268155
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of the VHL, HIF-1α, and VEGF Signaling Pathway and Associated MAPK (ERK1/2 and ERK5) Pathways in Clear-Cell Renal Cell Carcinoma. A Long-Term Study.
Salinas-Sánchez AS; Serrano-Oviedo L; Nam-Cha SY; Roche-Losada O; Sánchez-Prieto R; Giménez-Bachs JM
Clin Genitourin Cancer; 2017 Dec; 15(6):e923-e933. PubMed ID: 28624320
[TBL] [Abstract][Full Text] [Related]
12. VHL Expression in Kidney Cancer: Relation to Metastasis Development, Transcription and Growth Factors and Component of Akt/m-TOR Signaling Pathway.
Spirina LV; Kondakova IV; Yurmazov ZA; Usynin EA; Slonimskaya EM; Lushnikova NA; Podnebesnova DV
Bull Exp Biol Med; 2019 Sep; 167(5):671-675. PubMed ID: 31625068
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.
Gunningham SP; Currie MJ; Han C; Turner K; Scott PA; Robinson BA; Harris AL; Fox SB
Cancer Res; 2001 Apr; 61(7):3206-11. PubMed ID: 11306510
[TBL] [Abstract][Full Text] [Related]
14. HIFing the brakes: therapeutic opportunities for treatment of human malignancies.
Garcia JA
Sci STKE; 2006 May; 2006(337):pe25. PubMed ID: 16738063
[TBL] [Abstract][Full Text] [Related]
15. von-Hippel Lindau and Hypoxia-Inducible Factor at the Center of Renal Cell Carcinoma Biology.
Shirole NH; Kaelin WG
Hematol Oncol Clin North Am; 2023 Oct; 37(5):809-825. PubMed ID: 37270382
[TBL] [Abstract][Full Text] [Related]
16. Targeting vascular endothelial growth factor (VEGF)-receptor-signaling in renal cell carcinoma.
Reuter CW; Morgan MA; Grünwald V; Herrmann TR; Burchardt M; Ganser A
World J Urol; 2007 Mar; 25(1):59-72. PubMed ID: 17340158
[TBL] [Abstract][Full Text] [Related]
17. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway.
Carroll VA; Ashcroft M
Cancer Res; 2006 Jun; 66(12):6264-70. PubMed ID: 16778202
[TBL] [Abstract][Full Text] [Related]
18. Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine.
Audenet F; Yates DR; Cancel-Tassin G; Cussenot O; Rouprêt M
BJU Int; 2012 Jun; 109(12):1864-70. PubMed ID: 22035299
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas.
Roskoski R
Pharmacol Res; 2017 Jun; 120():116-132. PubMed ID: 28330784
[TBL] [Abstract][Full Text] [Related]
20. Genetic variation at the 8q24.21 renal cancer susceptibility locus affects HIF binding to a MYC enhancer.
Grampp S; Platt JL; Lauer V; Salama R; Kranz F; Neumann VK; Wach S; Stöhr C; Hartmann A; Eckardt KU; Ratcliffe PJ; Mole DR; Schödel J
Nat Commun; 2016 Oct; 7():13183. PubMed ID: 27774982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
